[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Maryland, Baltimore\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":630},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,123,0,25,[9,47,69,114,138,168,191,212,234,261,287,311,331,351,379,401,418,443,464,489,509,537,563,584,604],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100628600","transcriptomic-profile-changes-in-benign-tracheal-stenosis-wedge-resection-vs-radial-incision-100628600",false,"NCT07463742","Transcriptomic Profile Changes in Benign Tracheal Stenosis: Wedge Resection vs. Radial Incision","A Randomized Controlled Trial Comparing Transcriptomic Profile Changes Following Carbon Dioxide (CO2) Laser Wedge Resection Versus Radial Incision for Benign Tracheal Stenosis","Inclusion Criteria:\n\n* symptomatic tracheal stenosis\n* idiopathic subglottic stenosis\n* iatrogenic tracheal stenosis from intubation or tracheostomy\n\nExclusion Criteria:\n\n* positive ANA or ANCA\n* tracheal stenosis from infection, i.e. TB\n* tracheal stenosis with cartilage fracture\n* tracheal stenosis with malacia\n* tracheal stenosis from malignancy\n* tracheal stenosis from benign tumor\n* presence of glottic or supraglottic stenosis","ALL","18 Years","80 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Some people develop a narrowing of their windpipe (trachea), called benign tracheal stenosis, which can make it hard to breathe. Doctors often treat this by using a bronchoscope-a thin, flexible tube with a camera-to open up the airway or remove scar tissue. While these procedures help patients breathe better, we do not fully understand why the narrowing occurs or how the tissue heals afterward.\n\nThe purpose of this study is to better understand the biological changes in the airway tissue before and after these standard medical procedures. During the procedure, small samples of tissue that would already be collected as part of normal care will be analyzed in the laboratory. The results may help doctors learn more about airway healing and could guide better treatments in the future.",[28],"Tracheal Stenosis",[30,31,32,33],"tracheal stenosis","bronchoscopy","wedge resection","CO2 laser","RECRUITING","2026-08-18",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":38},"2026-05-01",{"date":42,"type":22},"2032-05-01",{"name":44,"class":45},"University of Maryland, Baltimore","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100486574","phase-3-antibiotic-cement-bead-pouch-versus-negative-pressure-wound-therapy-100486574","NCT05615844","Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy","A Randomized Controlled Trial Comparing Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy for the Management of Severe Open Tibia Fracture Wounds","BeadsvsVac","The inclusion criteria are:\n\n1. Patients 18 years of age or older.\n2. Severe open tibia fracture requiring more than one irrigation and debridement procedure to treat the open fracture.\n3. Planned internal or external fixation for definitive fracture management.\n4. Formal surgical debridement within 72 hours of their injury.\n5. Will have all planned fracture care surgeries performed by a participating surgeon or delegate.\n6. Informed consent obtained.\n\nThe exclusion criteria are:\n\n1. Due to the severity of injury, the treating surgeon does not believe limb salvage \\>6 months is likely to be successful based on the emergency department or initial intraoperative assessment (prior to enrolment and randomization).\n2. Medical contraindication to antibiotic beads, including previously known allergies or sensitivities to vancomycin and\u002For tobramycin.\n3. Medical or injury contraindication to NPWT. Injury contraindications could include situations in which the NPWT could not be placed over a vascular graft or exposed neurovascular structure.\n4. Received previous surgical debridement or management of their fracture at a non-participating hospital or clinic (as applicable).\n5. Chronic or acute infection at or near the fracture site at the time of initial fracture surgery.\n6. Incarceration.\n7. Women of child-bearing potential who are pregnant or intending to become pregnant within the next 6 months.\n8. Currently enrolled in a study that does not permit co-enrollment.\n9. Unable to obtain informed consent due to language barriers.\n10. Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.\n11. Prior enrollment in the trial.\n12. Other reason to exclude the patient, as approved by the Methods Center.",{"count":56,"type":22},312,[58],"PHASE3","The Beads vs Vac trial is a multi-centre randomized controlled trial of 312 participants with a severe open tibia fracture requiring multiple irrigation and debridement surgeries. Eligible participants will be randomized to receive either an antibiotic bead pouch or negative pressure wound therapy (NPWT) for their temporary open fracture wound management. Outcomes will be assessed at 6 weeks, 3 months, and 6 months post-surgery. The primary outcome will be a composite outcome to evaluate clinical status six months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) injury-related amputation of the lower extremity, 3) unplanned reoperation to manage wound complications, infection, or delayed fracture healing, and 4) clinical fracture healing as assessed using the Functional IndeX for Trauma (FIX-IT) instrument. The secondary outcomes will independently assess the four components of the primary outcome. This is a Phase III trial.",[61],"Open tíbia Fracture",{"date":37,"type":38},{"date":64,"type":38},"2023-11-05",{"date":66,"type":22},"2027-10-01",{"name":44,"class":45},34,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":96,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100625084","phase-2-a-single-arm-phase-ii-trial-in-p16-positive-oropharynx-cancer-of-selective-dose-de-escalation-of-nodal-volumes-at-minimal-risk-and-primary-site-disease-saved-100625084","NCT07418034","A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)","SAVED","4.1 Step 1 Registration 4.1.1 Step 1 Inclusion\n\n(Y) 1. Is there pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx or squamous cell carcinoma unknown primary? Note: specimen from cervical lymph nodes with a well-defined primary site documented clinically or radiologically is acceptable; in patients with carcinoma of unknown primary this will be sufficient for pathologic confirmation without a clinically or radiographically defined primary site.\n\n(Y) 2. Is the patient ≥ 18 years of age?\n\n(Y) 3. Did the patient provide study specific informed consent prior to study entry, including consent for mandatory submission of tissue for required p16 review?\n\n(Y) 4. Clinical TNM staging criteria by cohort (AJCC 8th edition):\n\nTORS candidate patients must be:\n\n• cT0-4 and N0, N1, N3\n\nNon-TORS candidate patients must be either:\n\n* cT1-4 N0, N1, N3\n* cT1-3 N2 with \\\u003C 10 pack years\n\n4.1.2 Step 1 Exclusion\n\n(N) 1. Patient who are clinical N2 and have ≥10 pack years smoking history\n\n(N) 2. Patients who are clinical T4N2\n\n(N) 3. Patients with distant metastasis (M1)\n\n4.2 Step 2 Registration 4.2.1 Step 2 inclusion\n\n(Y) 1. Does the patient have pathologically (histologically or cytologically) proven P16+ status?\n\n(Y) 2. Does the patient have appropriate imaging (PET\u002FCT preferred, CT neck with IV contrast and CT chest without contrast as recommended alternative to PET\u002FCT) completed within 90 days of enrollment?\n\n(Y) 3. Does the patient have clinical or pathological M0 staging? (Y) 4. Patients who have undergone TORS must have pathological stage pT1-4 N0, N1 or N3. TORS patients found to be clinical N2 post TORS or have contralteral neck dissection and positive nodes will be excluded.\n\n(Y) 5. Is the patient a candidate for bilateral radiation based on evaluation by ENT, Rad Onc, or Med Onc and review at multi-disciplinary tumor board?\n\n(Y) 6. Non-TORS patients who are cT1-3 N0, N1, N2 and have \\\u003C10 PY must have completed a ctDNA evaluation prior to Step 2 enrollment.\n\n(Y) 7. Non-TORS patients who are cT1-3 N2 must have a positive ctDNA result prior to Step 2 enrollment.\n\n(Y) 8. Was a general history and physical examination performed by a radiation oncologist, medical oncologist, or head and neck surgeon within 60 days prior to registration?\n\n(Y) 9. Was the patient's Zubrod Performance Status 0-1 within 30 days prior to registration?\n\n(Y) 10. If a woman of child-bearing potential or sexually active male, is the patient willing to use effective contraception throughout their participation in the treatment phase of the study and at least 180 days following the last study treatment.\n\n4.2.2 Step 2 Exclusion\n\n(N) 1. Does the patient have cancer considered to be from an oral cavity site (oral tongue, floor mouth, alveolar ridge, buccal or lip), nasopharynx, hypopharynx, or larynx?\n\n(N) 2. Does the patient have distant metastasis?\n\n(N) 3. Does the patient have prior invasive malignancy (except non-melanomatous skin cancer and low\u002Fintermediate risk prostate cancer) unless disease free for a minimum of 3 years?\n\n(N) 4. Did the patient have prior systemic chemotherapy for the study cancer (prior chemotherapy for a different cancer is allowable)?\n\n(N) 5. Did the patient have prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields?\n\n(N) 6. Did the patient have prior cancer-related surgeries of curative intent of the head and neck excluding superficial removal of cutaneous skin malignancies?\n\n(N) 7. Does the patient have any co-morbid condition or concern that may interfere with follow up per experimental arm?\n\n(N) 8. Does the patient have an active drug or alcohol dependency that in the opinion of the investigator would limit compliance with study requirements?\n\n(N) 9. Is the patient pregnant or nursing (an exception will be made for nursing patients that are not receiving chemotherapy)?",{"count":77,"type":22},132,[79],"PHASE2","Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have very good outcomes. Patients' treatment responses depend more on their individual cancer characteristics and personal risk factors than on the specific type of treatment they receive. However, the different treatments used for this cancer can cause significant side effects. Because outcomes are often favorable regardless of treatment type, reducing treatment-related side effects should be a priority when choosing care.\n\nStudies have reported that lowering radiation doses for some patients can reduce side effects while still effectively controlling the cancer.\n\nPatients with this type of head and neck cancer typically receive either surgery or radiation as their first treatment.\n\nFor patients who receive surgery first, radiation to the surgical area and nearby neck lymph nodes is often recommended afterward. In these patients, the study will test whether lowering the radiation dose to low-risk lymph nodes on the side of the neck opposite the tumor can reduce side effects while still effectively controlling the cancer (Method A).\n\nFor patients who receive radiation as their first treatment, the study will test one or both of two radiation approaches aimed at reducing both short-term and long-term side effects. These approaches include reduced lymph node radiation (Method A, described above) and a tumor dose reduction approach (Method B), which lowers the radiation dose delivered directly to the tumor.\n\nInformation such as tumor size, the number of cancerous or suspicious lymph nodes, and risk factors like smoking history will be used to determine which patients may be eligible for reduced lymph node radiation (Method A), reduced tumor radiation (Method B), or both. Patients who may qualify for tumor dose reduction (Method B), either alone or combined with Method A, will need an additional blood test called a circulating tumor DNA (ctDNA) test to determine eligibility.\n\nThe ctDNA test measures small amounts of tumor-related DNA in the blood, which are often elevated at the time of diagnosis. Studies have shown that cancer is more likely to return when ctDNA levels remain positive after treatment. This study will evaluate whether ctDNA levels measured before and during treatment can help identify patients who can safely receive lower radiation doses to the tumor (Method B).\n\nOverall, this study aims to safely evaluate two radiation de-escalation approaches in order to lessen short- and long-term side effects while maintaining excellent cancer control.",[82,83,84,85,86,87,88,89,90,91,92,93,94,95],"Head and Neck Cancer","Head and Neck Squamous Cell Cancer","Head and Neck Squamous Cell Carcinoma","Oropharyngeal Carcinoma","Oropharyngeal Squamous Cell Carcinoma (OPSCC)","Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma (SCC)","Oropharyngeal Squamous Cell Carcinoma (OPSCCA)","Oropharyngeal Cancer","Oropharyngeal Squamous Cell Cancer","HPV Positive Oropharyngeal Squamous Cell Carcinoma","HPV (Human Papillomavirus)-Associated Carcinoma","HPV 16 Positive Oropharyngeal Tumors (OPC)",[97,82,98,99,100,101,102,103,104],"Transoral Robotic Surgery (TORS)","Oropharynx Cancer","HPV p16 Oropharynx Cancer","Proton Therapy","Photon Therapy","Radiation Therapy","ctDNA","P16 positive","NOT_YET_RECRUITING","2026-08-11",{"date":108,"type":38},"2026-08-14",{"date":110,"type":22},"2026-09",{"date":112,"type":22},"2033-05",{"name":44,"class":45},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":46},"100600221","development-of-an-opioid-withdrawal-clinical-outcome-assessment-100600221","NCT07094672","Development of an Opioid Withdrawal Clinical Outcome Assessment","Development of an Opioid Withdrawal Clinical Outcome Assessment Among Persons With Opioid Use Disorder","Inclusion Criteria:\n\n* Past year opioid use disorder, determined by (a) enrollment in current treatment for opioid use disorder and\u002For (b) an opioid-positive saliva test.\n* Fluent in English\n* Has experience with opioid withdrawal at least once in the past 30 days\n\nExclusion Criteria:\n\n* Unable to provide informed consent due to cognitive impairment\n* Being pregnant or breastfeeding\n* History of psychosis or mania as determined by the MINI\n* Exhibiting suicidal behavior in the past 30 days as determined by the C-SSRS\n* Circumstances that could interfere with study participation\n* Previously participated in affiliated Focus Group study",{"count":122,"type":22},30,"OBSERVATIONAL","Withdrawal management strategies are currently the most utilized and ubiquitous intervention for opioid use disorder in the US, yet existing measures of opioid withdrawal lack Food and Drug Administration (FDA) qualification. This project will develop and validate a clinical outcome assessment (COA) for opioid withdrawal,essential for standardizing withdrawal mitigation strategies and establishing best practices. In line with the FDA's drug development tool qualification guidelines, our methodological process will involve conducting focus groups with persons with lived experience of opioid withdrawal for concept elicitation, refining these concepts through cognitive interviews, and conducting construct and longitudinal validations of the new assessment in laboratory settings and across diverse treatment contexts.",[126],"Opioid Use Disorder",[128,129,130,131],"opioid","fentanyl","withdrawal","naloxone",{"date":108,"type":38},{"date":134,"type":22},"2026-10-01",{"date":136,"type":22},"2028-09-30",{"name":44,"class":45},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":17,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":156,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":46},"100569209","photobiomodulation-and-tooth-analgesia-100569209","NCT06691269","Photobiomodulation and Tooth Analgesia","Evaluation of a Photobiomodulation Device for Dental Analgesia in Pediatric Patients","Inclusion Criteria:\n\n* Healthy children, aged 6-12 years, requiring routine dental treatment\n\nExclusion Criteria:\n\n* Children with uncooperative behavior or signficant medical history",true,"6 Years","12 Years",{"count":149,"type":22},200,[25],"The purpose of this study is to test photobiomodulation (PBM) with a non-invasive light device for reducing discomfort during dental treatments in children. We plan to conduct a series of three clinical studies in 200 school-aged children requiring routine dental treatment. The first study aims to test if PBM works for tooth and soft tissue by assessing response to cold testing and probing of gums. The second study aims to test if use of PBM on soft tissues before injection reduces discomfort. The third study aims to test if PBM can be used to do simple dental fillings in baby teeth without numbing injection.",[153,154,155],"Dental Anaesthesia","Dental Pain","Dental Analgesia",[157,158,159],"photobiomodulation","dental analgesia","dental anesthesia","2026-08-10",{"date":162,"type":38},"2026-08-12",{"date":164,"type":38},"2025-07-07",{"date":166,"type":22},"2027-06",{"name":44,"class":45},{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":175,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},"100624903","gccc-2578-randomized-photon-vs-proton-rt-for-newly-diagnosed-gynecologic-primaries-100624903","NCT07415681","GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries","A Phase II, Randomized, Open-Label, Single-Center Study Comparing Intensity Modulated Proton Therapy Versus Volume Modulated Arc Therapy in Patients Receiving Pelvic Nodal Irradiation for Newly Diagnosed Gynecologic Primaries","Inclusion Criteria:\n\n1. a. Newly diagnosed endometrial cancer after TAH\u002FBSO and nodal sampling, sentinel LN biopsy or pelvic nodal dissection planning to receive sequential chemotherapy and radiation or concurrent chemoradiotherapy or b. cervical cancer planning to receive definitive chemoradiation with HDR brachytherapy boost\n2. Histologic confirmation of malignancy (primary only)\n3. ≥ 18 years of age\n4. ECOG performance status ≤ 2\n5. Patient must have the ability to understand and the willingness to sign a written informed consent document or when appropriate, have an acceptable surrogate capable of giving consent on the subject's behalf.\n6. Insurance approval for IMPT\n\nExclusion Criteria:\n\n1. Metastatic disease beyond para-aortic lymph nodal region\n2. Residual tumor after surgery exceeding 2 cm in maximum dimension in patients with endometrial cancer.\n3. FIGO 2014 stage III-IVA cervix cancer planning to receive concurrent pembrolizumab.\n4. Cervical cancer with inability to receive concurrent chemotherapy.\n5. Any prior pelvic radiation.\n6. Treatment with other investigational agents.\n7. Carcinosarcoma.\n8. Creatine clearance \\\u003C30 mL\u002Fm2\n9. Unable to lie flat during or tolerate radiation.\n10. Refusal to sign informed consent.\n11. Any additional active cancer that would interfere with the primary study endpoints","FEMALE",{"count":177,"type":22},116,[79],"The purpose of study is to compare the side effects of two different forms of radiation for endometrial and cervical cancer. If you decide to enroll in this study, you will be randomized to one of two treatment groups. This study will compare two standard of care treatments: \"Conventional\" pHoton radiation versus pRoton radiation.",[181,182,102],"Gynaecologic Cancer","Cervical Cancer","2026-08-07",{"date":160,"type":38},{"date":186,"type":38},"2026-03-25",{"date":188,"type":22},"2033-12",{"name":44,"class":45},5,{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":145,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":46},"100592451","study-of-corneal-biomechanics-in-glaucoma-patients-using-brillouin-microscopy-100592451","NCT06993597","Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy","Development of Robust Corneal Biomechanical Biomarkers for Glaucoma Using Brillouin Microscopy","Inclusion Criteria:\n\n\\- Age 18 years or older\n\nDiagnosis of primary open angle glaucoma (POAG) or no history of glaucoma (for controls)\n\nOpen angle on gonioscopy (Shaffer grade 3 or 4)\n\nBest-corrected visual acuity of 20\u002F25 or better\n\nRefractive error between +3.00 and -5.00 diopters\n\nNo prior use of topical glaucoma medications\n\nDiagnosis of:\n\nHigh Tension Glaucoma (IOP ≥ 22 mmHg on 3 visits)\n\nNormal Tension Glaucoma (IOP ≤ 21 mmHg on 3 visits)\n\nOR age-matched control with normal optic nerve and visual fields\n\nExclusion Criteria:\n\nCorneal abnormalities or conditions interfering with Brillouin or applanation tonometry\n\nRetinal diseases affecting RNFL (e.g., macular traction)\n\nHistory of ocular surgery or laser\n\nDiagnosis of diabetes\n\nHistory of uveitis\n\nHistory of prolonged steroid use\n\nNeurodegenerative or systemic diseases (e.g., multiple sclerosis, Alzheimer's, Parkinson's, schizophrenia)\n\nUnreliable visual fields\n\nContraindications to beta blockers (e.g., bradycardia, severe pulmonary disease)\n\nModerate to severe glaucoma (per Hodapp-Anderson-Parrish criteria)\n\nHistory of contact lens use\n\nLow blood pressure",{"count":199,"type":22},60,"This pilot study evaluates the biomechanical properties of the cornea in glaucoma patients using Brillouin microscopy, a non-contact imaging technique. The study aims to compare corneal stiffness between patients with normal-tension glaucoma, high-tension glaucoma, and healthy controls, and to assess changes in corneal biomechanics following intraocular pressure (IOP)-lowering treatment. The goal is to determine whether Brillouin-derived biomechanical measurements can serve as biomarkers for glaucoma risk and progression.",[202],"Glaucoma",[204,205,206],"glaucoma","cornea","biomechanics",{"date":160,"type":38},{"date":209,"type":38},"2025-09-01",{"date":166,"type":22},{"name":44,"class":45},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100650481","phase-2-adaptive-chemotherapy-for-pd-l1-high-resectable-nsclc-a-chemo-phree-trial-100650481","NCT07746388","Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial","Inclusion Criteria:\n\n1. Age 18 years or older at time of study entry\n2. Eastern cooperative oncology group (ECOG) performance status of 0 or 1\n3. Participants with histologically confirmed stage II-IIIB(N2) NSCLC (per the 9th International Association for the Study of Lung Cancer) with disease that is considered resectable prior to initiation of systemic therapy.\n4. Subject cases must be reviewed in a multidisciplinary thoracic tumor board setting prior to enrollment to allow for adequate discussion regarding the appropriateness for resection.\n5. Participants must have a tumor tissue sample available for biomarker testing, including PD-L1 IHC testing and sequencing to confirm EGFR\u002FALK status. Assessment of PD-L1 IHC, EGFR\u002FALK status may be performed locally through a CLIA approved laboratory testing method.\n\n   a. Tissue source may be a formalin fixed paraffin block (FFPE) of a previous tumor biopsy sample. Source of biomarker testing may be obtained from archived tissue if adequate or from a new biopsy, if needed and clinically indicated.\n6. Participants must have established PD-L1 Tumor Proportion Score (TPS) expression \\> or equal to 50%, assessed locally through a CLIA approved laboratory testing method.\n7. All suspicious mediastinal\u002Fhilar lymph nodes including those that are pathologically enlarged or FDG avid on PET\u002FCT require further sampling for pathological confirmation if accessible by mediastinoscopy, thoracoscopy, or EBUS.\n8. Absence of major associated pathologies that increase the surgery risk to an unacceptable level\n9. Pulmonary function capacity (eg. FVC, FEV1, TLC, and DLCO) capable of tolerating proposed lung resection according to surgeon.\n10. Adequate normal organ and marrow function defined below:\n\n    1. Platelet count \\> or equal to 100,000\u002Fmm3\n    2. Hemoglobin \\> or equal to 8 g\u002FdL\n    3. Absolute neutrophil count (ANC) \\> or equal to 1000\u002Fmm3\n    4. Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) \\> or equal to 40 mL\u002Fmin\n    5. Total bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome who can have total bilirubin \\\u003C 3.0 mg\u002FdL)\n\nAST, ALT, Alkaline phosphatase ≤ 3 x ULN per local testing 11. Subjects are deemed capable of giving informed consent and must have signed and dated an IRB approved written informed consent form. This written consent must be obtained before the performance of any protocol related procedures that are not part of normal standard of care. 12. Women of childbearing potential (WOCBP) must have negative serum or urine pregnancy testing within 30 days of study start\n\nExclusion Criteria:\n\n1. Presence of locally advanced unresectable (regardless of stage) or metastatic disease (stage IV).\n2. Participants with large-cell neuroendocrine carcinoma tumor or small cell carcinoma histology, including those with presence of mixed histology.\n3. Participants with known sensitizing EGFR mutations (L858R, Exon 19 deletion, Exon 20 insertion, atypical mutations including G719X L861Q, S768I) or ALK translocation via local CLIA approved testing methods.\n\n   a. For patients in whom more comprehensive testing is performed, those with identified targetable alterations in ROS1, NTRK, RET, METex14, HER2 genes will also be excluded. Screening for these specific alterations (ROS1\u002FNTRK\u002FRET\u002FMETex14\u002FHER2), however, are not required for enrollment.\n4. Participants with brain metastases are excluded from this study. All patients should have pre-study MRI brain or CT head with contrast to confirm the absence of intracranial disease, per standard of care staging procedures.\n5. Prior therapy with an anti-PD-(L)1, anti-CTLA-4 antibody or any other antibody targeting t-cell co-regulatory pathways.\n6. Active prior malignancy within the previous 3 years, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast.\n7. History of allogeneic organ transplantation.\n8. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n9. New York Heart Association heart failure classifications of Class II, III, or IV; or myocardial infarction, or acute coronary syndrome within 12 months of first dose of study medication; or Transient ischemic attack or stroke within 1 year\n10. Any condition that requires ongoing\u002Fcontinuous corticosteroid therapy (\\>10 mg prednisone\u002Fday or anti-inflammatory equivalent) within 1 week prior to the first dose of study medication. Participants who require a brief course of steroids (up to 2 days in the week before enrollment) or physiologic replacement are not excluded.\n11. Ongoing or significant autoimmune disease that required treatment with systemic immunosuppressive treatments within the last 5 years. Note: The following are not exclusionary: vitiligo, childhood asthma that has resolved, endocrinopathies (such as hypothyroidism or type 1 diabetes) that require only hormone replacement, or psoriasis that does not require systemic treatment.\n12. Any infection requiring hospitalization or treatment with IV anti-infectives within 2 weeks of first dose of study medication\n13. Uncontrolled infection with HIV, hepatitis B or hepatitis C infection, diagnosis of immunodeficiency, and\u002For tuberculosis (active or latent).\n\n    1. Participants with known controlled HIV infection (undetectable viral load on HIV RNA PCR) and CD4 count above 350 either spontaneously or on a stable antiviral regimen are eligible. For these participants monitoring will be performed per local standards.\n    2. Participants with HBsAg positive who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for hepatitis B) are eligible. Participants with controlled infections must undergo periodic monitoring of HBV DNA. Participants must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study medication.\n    3. Participants with HBsAg negative but total HBcAb positive are permitted with the following requirements: If serum HBV DNA PCR is above the limit of detection at screening, initiate HBV antiviral therapy before study entry. If serum HBV DNA PCR is below the limit of detection, periodic monitoring of HBsAg must be performed.\n    4. Participants who are HCV Ab+ who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in eligible\n14. Receipt of a live vaccine within 4 weeks of start of study medication\n15. Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.\n16. Known hypersensitivity to the active substances or to any of the excipients.\n17. WOCBP\\* and men\\*\\* who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment, during the study, and for at least 4 months after the last dose of cemiplimab. Highly effective contraceptive measures include:\n\n    1. Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening;\n    2. Intrauterine device; intrauterine hormone-releasing system;\n    3. Bilateral tubal occlusion\u002Fligation;\n    4. Vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure); and\u002For\n    5. Sexual abstinence†,‡. Pregnancy testing and contraception are required for WOCBP. Pregnancy testing and contraception are not required for women who are postmenopausal or permanently sterile.\n\n       * WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a postmenopausal state. The above definitions are according to the CTFG guidance. Pregnancy testing and contraception are not required for women with documents hysterectomy or tubal ligation. \\*\\*Male participants: A male participant will be excluded from the study if that participant does not agree to use condoms or practice sexual abstinence†‡, unless vasectomized, prior to the initial dose\u002Fstart of study medication, during the study, and for at least 4 months after the last dose of cemiplimab. Sperm donation is also prohibited during the same period. Vasectomy success must be confirmed by semen analysis. †Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drugs. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. ‡Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.",{"count":122,"type":22},[79],"This research study is being done to find out if a drug called cemiplimab is safe in adult patients who have non-small cell lung cancer (NSCLC) that can be surgically removed (resectable Stage II, IIIA, or select IIIB NSCLC). The purpose of this study is also to look at how well the study drug works and whether certain patients can skip chemotherapy before their surgery. The goal is to see if they can safely avoid the harsh side effects of chemo and still have a successful outcome.\n\nThe investigators are doing this study because the investigators want to find out if this treatment approach is better or worse than the usual approach for early-stage NSCLC that can be surgically removed. The usual approach for the participants type of cancer is treatment with a combination of platinum-doublet chemotherapy and an immune checkpoint inhibitor (ICI) such as cemiplimab (LIBTAYO®) given before the tumor is surgically removed. (Immune checkpoint is a normal part of the immune system used to prevent an immune response from becoming so strong that it inadvertently destroys healthy cells in the body).\n\nCemiplimab is given via infusion and will be administered at the study center. Everyone on the study will get the active study drug, cemiplimab. No one will get placebo. Placebos look like the study drug but don't have medicine in them.\n\nInfusion of cemiplimab will be given for 2 cycles followed by an evaluation. An evaluation means that participants will have imaging studies (\"scans\") done to see if the tumor has changed. After the scans, participants may receive one final cycle of cemiplimab followed by resection (surgery to remove the tumor) or combination chemotherapy plus cemiplimab for 2 cycles followed by resection.",[222,223,224,225,226],"Nsclc","NSCLC Stage II","NSCLC, Stage III","NSCLC Stage IIIB","Resectable Lung Non-Small Cell Carcinoma","2026-08-04",{"date":183,"type":38},{"date":230,"type":22},"2026-09-01",{"date":232,"type":22},"2031-09-01",{"name":44,"class":45},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":145,"sex":17,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":251,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":258,"leadSponsor":260,"locationsCount":46},"100647847","internal-irrigation-surgery-100647847","NCT07715825","Internal Irrigation Surgery","Evaluation of an Internal Irrigation Surgical Guide to Reduce Heat Generation During Dental Implant Surgery","Inclusion Criteria:\n\n1. Patients aged 25+\n2. Patients requiring a dental implant in the maxilla or mandible\n3. Patients with sufficient bone volume for implant placement.\n4. Patients classified as ASA I or II based on the American Society of Anesthesiologists (ASA) physical status classification system.\n5. Patients capable of providing informed consent and willing to adhere to study procedures and follow-up appointments.\n6. Patients with adequate interarch space to accommodate guided implant surgery.\n7. No history of implant placement at the experimental or control site.\n\nExclusion Criteria:\n\n1. ASA class 3 or higher\n2. Currently undergoing or history of bisphosphonate or antiresorptive therapy\n3. Patients who have received prior radiation therapy to the head and neck.\n4. Patients with contraindications for implant placement, such as active infections or severe periodontal disease.\n5. Pregnant or breastfeeding\n6. Patients with psychiatric or cognitive conditions impairing informed consent or compliance","25 Years","75 Years",{"count":21,"type":22},[25],"Heat generated during osteotomy and implant placement may cause thermal injury to bone and adversely affect healing and osseointegration. External irrigation is commonly used to reduce heat generation; however, cooling may be less effective at the drill-bone interface, particularly during guided implant surgery.\n\nSurgical guides with integrated irrigation channels have been developed to deliver coolant more directly to the osteotomy site, but clinical evidence regarding their effectiveness remains limited. This study will evaluate whether an internal irrigation surgical guide system reduces heat generation during osteotomy compared with a conventional guided implant surgery approach. The study will also assess clinical outcomes associated with implant placement. The findings may help inform safer and more effective protocols for guided dental implant surgery.",[247,248,249,250],"Dental Implant Healing","Partial Edentulism Class 1","Partial Edentulism Class II","Partial Edentulism Class 3",[252,253],"dental implant surgery","dental implant placement","2026-08-03",{"date":256,"type":38},"2026-08-06",{"date":230,"type":22},{"date":259,"type":22},"2028-12-31",{"name":44,"class":45},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":145,"sex":269,"minAge":18,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":286},"100564105","phase-2-evaluating-gardasil-hpv-vaccine-humoral-and-cellular-immune-responses-in-people-with-and-without-hiv-100564105","NCT06624839","Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV","A PRe-pOsT Interventional Study Evaluating Gardasil Nine-valent Human Papilloma Virus (HPV) Vaccine Humoral and Cellular Immune Responses in People With or Without HIV","PROTECT","Inclusion Criteria:\n\n* 18 years old or older and 70 years old or younger\n* Able to provide informed consent\n* Denies history of prior HPV vaccination with Gardasil9 (receipt of HPV vaccination other than Gardasil9 such as the bivalent or the quadrivalent HPV vaccine will be allowed) or unsure of vaccination status and born before 2003\n* Born Male\n\nFor Test group: HIV-positive people born male with current or past exposure to androgen blockers or estrogen (BM-EABE)\n\n* Living with HIV\n* Current or past exposure to androgen blockers or estradiol\n\nFor Control group: HIV-negative Control\n\n* HIV negative\n* Either: Current or past exposure to androgen blockers or estradiol; no current or past exposure to androgen blockers or estradiol AND had sex with a person with a penis in the last year\n\nExclusion Criteria:\n\n* Younger than 18 years old or older than 70 years old.\n* Self-reported or documented history of nine-valent HPV vaccine or unsure of vaccination status and born after 2003.\n* Born female\n* History of hypersensitivity, including severe reactions to yeast or other component of the vaccine.\n* Any condition requiring systemic chemotherapy or immunomodulant affecting antibody responses (i.e., rituximab, ibrutinib etc.), intravenous or subcutaneous immunoglobulin supplementation, radiation therapy, or immunomodulatory treatment within the previous 6 months (presence of precancerous lesions is not exclusionary).","MALE","70 Years",{"count":272,"type":22},120,[79],"This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose).",[276,277,278],"Human Papilloma Virus","Anal Dysplasia","HIV",{"date":280,"type":38},"2026-08-05",{"date":282,"type":38},"2025-03-15",{"date":284,"type":22},"2028-01",{"name":44,"class":45},2,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":17,"minAge":293,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100572644","the-volunteering-in-place-program-for-apathetic-assisted-living-residents-with-adrd-100572644","NCT06735950","The Volunteering-in-Place Program for Apathetic Assisted Living Residents With ADRD","Inclusion Criteria:\n\n* age 55 years or older;\n* English speaking;\n* live in the included AL community\n* have mild to moderate cognitive impairment based on a SLUMS score of 26 or below and the ability to follow a one-step command.\n* have apathy based on a \"yes\" answer to at least 2 questions on the apathy subscale of the Neuropsychiatric Inventory (NPI) completed by a family or staff member who has had close contact with the resident in the past month;\n* have an anticipated length of stay of 12 months.\n\nExclusion Criteria:\n\n\\- refusal to assent","55 Years",{"count":149,"type":22},[25],"This is a research study to test two different interventions to decrease apathy in assisted living residents with some memory issues. Apathy makes older adults not feel like doing much activity. This study is completely voluntary and will not affect the care you receive at your assisted living community.\n\nThe two possible interventions are 1) participation in a volunteering opportunity within the assisted living community OR 2) participation in a guided current events group within the assisted living community. These activities would be in addition to any other regular activities you participate in within the assisted living community. Both activities would take place three days per week for approximately 30 minutes. You would be randomly assigned (like a coin flip) to which intervention you would do. You do not get to choose. You would participate in the activity for a total of 6 months.\n\nIn addition to participating in the intervention (either volunteering or current events), you will be asked to answer some questions about your memory, level of activity, mood, confidence in your ability to do a volunteer job, and feelings of usefulness. You will answer these questions at baseline (before the activity begins, at 3 months after doing the intervention activity, and aging at 6 months after starting the interventions activity. You will also be asked to wear a MotionWatch for 5 days at each time point (baseline, 3months and 6 months). A motion watch measures your level of activity. It feels like wearing a regular watch. You will be in the study for 6 months total.\n\nRisks to participating in this study are minimal and include privacy (other people may find out you are in the study), confidentiality of the data collected if someone other than study staff accesses your records, fatigue with answering the questionnaires, and some mild discomfort with wearing the MotionWatch. This is also a minor risk that you could fall or otherwise harm yourself getting to or participating in your intervention activity.\n\nThe benefit of participating in this study include possible enjoyment of participating in the intervention activity.",[298],"Apathy in Dementia",[300,301,302,303],"apathy","assisted living","dementia","volunteering","2026-07-31",{"date":254,"type":38},{"date":307,"type":22},"2026-08-29",{"date":309,"type":22},"2027-08-31",{"name":44,"class":45},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":145,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":330,"locationsCount":46},"100502062","implementation-of-anal-cancer-screening-and-treatment-in-nigeria-100502062","NCT05817370","Implementation of Anal Cancer Screening and Treatment in Nigeria","Integrated Model for the Prevention of Anal Cancer Using Screen and Treat for High-grade Intraepithelial Lesions (IMPACT)","IMPACT","Inclusion Criteria:\n\n1. Possess a medical degree in medical sciences (MBBS or equivalent)\n2. At least 2-5 years of experience working with clinical HIV\u002FAIDS community\n3. Must be registered with the medical and dental council of Nigeria\n4. Possess a current medical practicing license\n5. Willing to work with the Sexual Gender Minority Community\n\nExclusion Criteria:",{"count":46,"type":22},[25],"The study is a feasibility pilot trial testing 2 types of training protocols on a single physician. The first training protocol is the current standard and was developed in high-income settings. The second training protocol will be developed so tailored to the Nigerian setting. Investigators will test if the physician performs differently in their ability to conduct anal cancer screening and treatment between the 2 training protocols.",[323],"Education, Medical","2026-07-29",{"date":326,"type":38},"2026-07-30",{"date":328,"type":38},"2023-05-02",{"date":309,"type":22},{"name":44,"class":45},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":339,"conditions":340,"keywords":342,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":348,"leadSponsor":350,"locationsCount":46},"100633572","signature-development-and-validation-protocol-for-an-epigenetic-assay-in-diagnosing-pancreatic-cancer-100633572","NCT07528430","Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer","Inclusion Criteria:\n\n* 18 years old or older\n* Patient of UMMS\n* Willing and able to consent to study procedures listed in the protocol\n* Ability to speak and understand English\n* Has a history of pancreatic cancer of is at high risk for pancreatic cancer\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Patient not cared for at UMMS\n* Unable to consent to study procedures listed in the protocol\n* Unable to speak or understand English\n* Does not have a history of pancreatic cancer or is not at high risk for pancreatic cancer",{"count":338,"type":22},450,"The purpose of this research study is to test a new process for diagnosing pancreatic cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.\n\nParticipants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.",[341],"Pancreatic Cancer, Advanced or Metastatic",[343,344],"Pancreatic cancer","Pancreatic cancer screening","2026-07-27",{"date":324,"type":38},{"date":230,"type":22},{"date":349,"type":22},"2032-11",{"name":44,"class":45},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":358,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":363,"conditions":364,"keywords":366,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":376,"leadSponsor":378,"locationsCount":4},"100594027","robot-aided-off-axis-neuromuscular-training-for-knee-oa-100594027","NCT07014098","Robot-Aided Off-Axis Neuromuscular Training for Knee OA","Effectiveness of Robot-Aided Off-Axis Neuromuscular Training for Knee Osteoarthritis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 45 - 85 years.\n* Meets the ACR classification criteria for knee OA (clinical + radiographic criteria); Kellgren-Lawrence grade I-III.\n* Persistent knee pain ≥ 3 months.\n* Able to independently complete elliptical training (6 minutes without interruption).\n\nExclusion Criteria:\n\n* Other inflammatory joint diseases (e.g., rheumatoid arthritis).\n* Knee trauma, surgery, or intra-articular injections within the past year.\n* History of knee or hip replacement.\n* Cardiovascular disease or uncontrolled hypertension contradict to exercises.\n* Cognitive impairment (Montreal cognitive assessment \\\u003C 22).\n* Currently participating in another interventional study for the lower limb.\n* Neurological impairment (e.g., stroke, Parkinson's disease, radicular pain).","45 Years","85 Years",{"count":361,"type":22},36,[25],"Although the primary knee motion occurs in flexion\u002Fextension, the frontal and transverse (off-axis) knee motions are smaller but crucial for maintaining joint stability and normal knee loading. Altered kinematics and neuromuscular control in off-axis knee motions have been reported in patients with knee osteoarthritis (OA), which are associated with excessive knee loading and the progression of knee OA. However, traditional rehabilitative treatments for people with knee OA and existing exercise equipment often focus on sagittal plane movement. Probably due to the technical limitations, there is a lack of convenient and effective equipment\u002Fmethod to train patients with knee OA in off-axis (frontal and transverse) planes.\n\nThe purpose of this study is to use a robot-aided elliptical training device to measure knee neuromechanical properties and to improve neuromuscular control in off-axis knee motions, aiming for joint de-loading and pain reduction for individuals with knee OA.",[365],"Osteoarthritis of Knee",[367,368,369,370,371,372],"knee osteoarthritis","robot-assisted","neuromuscular training","knee biomechanics","knee symptoms","evaluation-based training strategy",{"date":374,"type":38},"2026-07-28",{"date":230,"type":22},{"date":377,"type":22},"2030-01",{"name":44,"class":45},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":145,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":387,"conditions":388,"keywords":393,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":46},"100593609","signature-development-and-validation-protocol-for-an-epigenetic-assay-in-diagnosing-lung-cancer-100593609","NCT07008664","Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer","Inclusion Criteria:\n\n* 18 years old or older\n* Patient at University of Maryland Baltimore Washington Medical Center\n* Willing and able to consent to study procedures listed in the protocol\n* Ability to speak and understand English\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Patient not cared for at University of Maryland Baltimore Washington Medical Center\n* Unable to consent to study procedures listed in the protocol\n* Unable to speak or understand English",{"count":386,"type":22},750,"The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.\n\nParticipants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.",[389,390,391,392],"Lung Cancer","Lung Cancer Screening","Healthy Volunteers (HV)","Unhealthy Volunteers",[389,390,394,392],"Healthy Volunteers",{"date":324,"type":38},{"date":397,"type":38},"2025-03-31",{"date":399,"type":22},"2032-04",{"name":44,"class":45},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":415,"leadSponsor":417,"locationsCount":46},"100582563","exploration-of-novel-imaging-biomarkers-on-oct-for-ublituximab-treatment-response-in-multiple-sclerosis-100582563","NCT06864936","Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis","Inclusion Criteria:\n\nFor Ublituximab Group:\n\n1. Ages 18-65\n2. A diagnosis of relapsing MS (to include relapsing-remitting MS and active secondary progressive MS) according to 2017 Revised McDonald Criteria.\n3. A recent referral for initiation of ublituximab for treatment of MS by the patient's treating physician.\n\nFor Comparison Group:\n\n1. Ages 18 - 65\n2. A diagnosis of relapsing-remitting MS according to 2017 Revised McDonald Criteria.\n3. Currently on a stable dose of disease modifying treatment for MS with no plans for alternative therapy for the following year.\n\nExclusion Criteria:\n\nFor Ublituximab Group:\n\n1. Known eye disease that may, in the opinion of the screening ophthalmologist, preclude proper analysis of data in this study. This includes, but is not limited to diabetic retinopathy, macular degeneration, and glaucoma.\n2. Treatment with any B-cell depleting disease modifying therapy for MS (i.e. rituximab, ocrelizumab, ofatumumab, ublituximab, etc.) within the past 12 months.\n3. History of life-threatening infusion reaction on ublituximab or prior anti-CD20 therapy\n4. Any chronic or active infection that would preclude anti-CD20 therapy. This may include but is not limited to active hepatitis B virus (HBV) confirmed by positive results for Hepatitis B surface antigen (HBsAg) and anti-HBV tests, tuberculosis, and human immunodeficiency virus (HIV).\n5. Receipt of any live of live-attenuated vaccines within 4 weeks prior to first ublituximab administration\n\nFor Comparison Group:\n\n1. Known eye disease that may, in the opinion of the screening ophthalmologist, preclude proper analysis of data in this study. This includes, but is not limited to diabetic retinopathy, macular degeneration, and glaucoma.\n2. Treatment with any B-cell depleting disease modifying therapy (i.e. rituximab, ocrelizumab, ofatumumab, ublituximab, etc.) within the past 12 months, or plans to initiate such a therapy in the following year.","65 Years",{"count":122,"type":22},[25],"The purpose of the research study is to explore new retinal imaging biomarkers of immune cell activity in MS during use of ublituximab (Briumvi) treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. This study will evaluate the efficacy of ublituximab to modulate MS pathology in a new manner. In order to assess this new biomarker, a specialized optical coherence tomography (OCT) scan will be performed at enrollment into the study and at 2 other timepoints throughout the study.\n\nSubjects asked to take part in this study should have been diagnosed with relapsing multiple sclerosis (MS) and have recently been advised to start the medication ublituximab (Briumvi) or are currently on another medication for the treatment of their MS.\n\nWe plan to enroll 30 patients into this study. Fifteen (15) patients with Relapsing Remitting Multiple Sclerosis (RRMS) who are being initiated on B-cell depletion therapy by their treating physician at the University of Maryland Center for MS Treatment and Research will be offered enrollment into this study. Additionally, 15 age\u002Fsex matched patients with stable RRMS who are not undergoing any change in treatment and are not currently on B-cell depleting therapies will be enrolled as control subjects.",[412],"Multiple Sclerosis (MS) - Relapsing-remitting",{"date":324,"type":38},{"date":40,"type":38},{"date":416,"type":22},"2028-01-30",{"name":44,"class":45},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":175,"minAge":18,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":23,"phases":427,"briefSummary":429,"conditions":430,"keywords":433,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":46},"100531388","early-phase-1-induction-of-labor-in-morbidly-obese-patients-100531388","NCT06199154","Induction of Labor in Morbidly Obese Patients","Induction of Labor in Morbidly Obese Patients: Comparison of 50 mcg and 25 mcg Misoprostol - A Randomized Control Trial","Inclusion Criteria:\n\n* Morbidly obese (BMI ≥ 40 kg\u002Fm2) at admission for induction of labor\n* Speaks English or Spanish\n* Gestational age between 34 weeks and 0 days and 42 weeks and 6 days\n* Age 18 years old or older\n* Viable, single, cephalic fetus\n* Intent to proceed with cervical ripening - cervical exam: dilation \\\u003C 5 cm\n* Contractions \\\u003C 5 per 10 minutes\n\nExclusion Criteria:\n\n* History of cesarean delivery\n* Contraindication to prostaglandin administration (significant myomectomy, prior cesarean delivery)\n* Contraindication to vaginal delivery (placenta previa, vasa previa, HIV with high viral load)\n* Contraindications to labor (cardiac, neurosurgical, need for cesarean)\n* Age \\\u003C 18yo\n* Fetal growth restriction with abnormal umbilical artery Doppler indices\n* Cervical dilation \\>5 cm\n* Contractions \\>5 per 10 minutes\n* Significant vaginal bleeding with concern for placental abruption\n* Non-reassuring fetal status or fetal heart rate decelerations\n* Fetal demise or major fetal anomaly\n* Inability to give consent",{"count":426,"type":22},162,[428],"EARLY_PHASE1","The goal of this randomized control trial is to compare different doses of Misoprostol (25 mcg vs 50 mcg) in induction of labor (IOL) in morbidly obese patients with BMI \\>40. It is known that morbid obesity is a risk factor for failed IOL and ultimately cesarean delivery (CD.) If the rates of vaginal delivery in this population can improve, then surgical morbidity can be reduced in these patients.",[431,432],"Morbid Obesity","Pregnancy",[434,435,436],"induction of labor","morbid obesity","misoprostol",{"date":324,"type":38},{"date":439,"type":38},"2024-07-15",{"date":441,"type":22},"2027-05",{"name":44,"class":45},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":242,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":46},"100478587","phase-2-evaluating-buspirone-to-treat-opioid-withdrawal-100478587","NCT05511909","Evaluating Buspirone to Treat Opioid Withdrawal","Evaluating a Mechanistically-Supported Pharmacotherapy to Treat Opioid Withdrawal","Inclusion Criteria:\n\n* Aged 18-75\n* Opioid positive urine sample\n* Current moderate-severe opioid use disorder with evidence of physical dependence\n* Interested in undergoing opioid detoxification\n\nExclusion Criteria:\n\n* Being pregnant or breastfeeding\n* Enrolled in methadone or buprenorphine maintenance treatment\n* Allergic to study medication or taking medications that are contraindicated with study medication (e.g., CYP3A4 inhibitors or inducers and\u002For monoamine oxidase (MAO) inhibitors)\n* Significant mental health or physical disorder, or life circumstance, that is expected to interfere with study participation (detailed further in protection of human subjects form).\n* Hypotension and\u002For prolonged QTc interval",{"count":451,"type":22},100,[79],"The investigators propose a rigorous, Phase II, three-group, placebo-controlled double-blind randomized controlled trial (RCT) to evaluate the efficacy of buspirone for both withdrawal and craving among individuals with opioid use disorder (OUD) undergoing a standardized stepwise taper. During this 10 to 12-day residential study, participants with OUD will be enrolled, stabilized on a short-acting opioid, undergo an opioid stepwise taper, and complete a post-taper observation period where participants will have the opportunity to initiate long-term buprenorphine or extended-release naltrexone.",[126,455,456,457],"Opioid Withdrawal","Opioid Craving","Anxiety",{"date":374,"type":38},{"date":460,"type":38},"2023-03-15",{"date":462,"type":22},"2027-03-31",{"name":44,"class":45},{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":23,"phases":473,"briefSummary":474,"conditions":475,"keywords":477,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":4},"100649591","feasibility-and-acceptability-of-olp-exp-in-chronic-pain-100649591","NCT07735520","Feasibility and Acceptability of OLP-EXP in Chronic Pain","Evaluating the Feasibility and Acceptability of Expectation-optimized Open-label Placebo as an Adjuvant Treatment for Chronic Pain","Inclusion Criteria:\n\n* English speaking (written and spoken)\n* Age between 18 and 65 years\n* Confirmed TMD for more than 3 months\n* Grade II or above on the Graded Chronic Pain Scale\n\nExclusion Criteria:\n\n* Personal (or family first degree) history of mania, schizophrenia, or other psychoses\n* Severe psychiatric conditions require medication (e.g. schizophrenia, bipolar disorders, autism) or hospitalization within the last 3 years.\n* Lifetime alcohol\u002Fdrug dependence and alcohol\u002Fdrug abuse in past one year\n* Pregnancy\u002FBreastfeeding\n* Currently participating in another clinical trial",{"count":472,"type":22},57,[25],"The primary objective is to determine the feasibility of delivering OLP-EXP, EXP only, and OLP only over 6 weeks to adults with chronic TMD. The trial will be considered feasible for progression planning when the 6-week retention rate is at least 80% in each arm and average OLP pill adherence is at least 80% of prescribed days in each OLP arm.\n\nPrimary hypothesis: Each intervention arm will meet the prespecified 6-week retention benchmark, and each OLP arm will meet the prespecified pill-adherence benchmark.\n\nThe secondary objectives are:\n\n1. To evaluate acceptability of each intervention using the TFA measurement and semi-structured interviews.\n2. To assess the feasibility of collecting daily EMA, continuous actigraphy, weekly questionnaires, and 3-, 6-, and 12-month follow-up assessments.\n3. To identify intervention barriers, facilitators, perceived benefits, burden, ethical concerns, and recommendations for a future fully powered efficacy trial.\n4. To estimate variability, missingness, and measure reliability needed to select outcomes and design a future trial.",[476],"Temporomandibular Disorders (TMD)",[478,479,480,481],"expectations","chronic pain management","open-label placebo","psychological interventions","2026-07-24",{"date":326,"type":38},{"date":485,"type":22},"2027-07-01",{"date":487,"type":22},"2029-12-31",{"name":44,"class":45},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":145,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":46},"100599973","phase-4-biotivity-a-c-membrane-socket-preservation-study-100599973","NCT07091448","Biotivity A-C Membrane Socket Preservation Study","Prospective, Assessment of Alveolar Ridge Preservation Using Biotivity™ Amnion Chorion Membranein Atraumatic Extraction Socket","Inclusion criteria:\n\n1. Provision of informed consent\n2. At least 18 years old\n3. In need of one posterior tooth (premolar or molar), excluding third molars, planned for extraction and replacement with a dental implant\n4. Type I or II extraction socket\u002F ridge identified at the time of enrolment with cone-beam CT scan\n5. At least one retained natural tooth adjacent to the study site\n\nExclusion criteria\n\n1. Insufficient interocclusal or interdental space to allow for an implant- supported prosthesis\n2. Previous interventions performed involving soft and\u002For bone grafting in the study site\n3. Active caries\n4. Uncontrolled periodontal disease present\n5. Evidence of active periapical, radicular, or endodontic lesions on teeth adjacent to study site\n6. History of recent extraction of an adjacent tooth (mesial and distal) to study site within 6 months of enrollment\n7. Current smoker with self-reported history of more than 10 cigarettes or equivalent per day\n8. Self-reported use of smokeless tobacco or e-cigarette\n9. Self-reported history of current alcohol or drug abuse\n10. Systemic or local disease or condition that would compromise bone metabolism, post-operative healing and\u002For osseointegration e.g. uncontrolled diabetes with self-reported most recent HbA1c \\> 8.0 within last six-month13,14\n11. Systemic corticosteroids or any other medication that would influence bone metabolism, post-operative healing, and\u002For osseointegration\n12. Pregnancy, as confirmed by a urine pregnancy test at screening.",{"count":497,"type":22},12,[499],"PHASE4","This is a prospective, randomized controlled pilot clinical trial evaluating the efficacy of a human placental-derived amnion chorion membrane (Biotivity™ A\u002FC Plus Membrane) versus a conventional collagen membrane in alveolar ridge preservation (ARP) following atraumatic extraction of single posterior teeth. A total of 12 subjects will be enrolled at the University of Maryland School of Dentistry. The study aims to assess both soft tissue wound healing and hard\u002Fsoft tissue dimensional changes over a 5-month period prior to dental implant placement.\n\nThroughout the approximately 6-month study duration, participants will undergo oral exams, x-rays, surgical procedures, and follow-up visits. All participants will undergo routine tooth extraction, bone graft material and barrier placement, and dental implant placement.\n\nParticipation in the study is voluntary, and the alternative is to continue routine dental care. Risks include minor discomfort from procedures such as tooth extraction and implant placement. The major benefit of participation in the study is the preservation of jaw dimensions following extraction, which will simplify the placement of a dental implant.",[502],"Alveolar Ridge Preservation",{"date":345,"type":38},{"date":505,"type":22},"2026-08-01",{"date":507,"type":22},"2028-10-31",{"name":44,"class":45},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":145,"sex":17,"minAge":18,"maxAge":516,"enrollmentInfo":517,"targetDuration":4,"studyType":23,"phases":519,"briefSummary":521,"conditions":522,"keywords":525,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":46},"100444781","phase-1-pharmacogenetics-of-response-to-glp1r-agonists-100444781","NCT05071898","Pharmacogenetics of Response to GLP1R Agonists","PORT","Inclusion Criteria:\n\n* BMI greater than or equal to 27 kg\u002Fm2\n* Of Amish Descent\n\nExclusion Criteria:\n\n* Woman of childbearing age who is sexually active\n* History of diabetes (HbA1c \\> 6.5% or random glucose \\>200 mg\u002FdL)\n* Known allergy to semaglutide\n* Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study\n* eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 sq. m.\n* Hematocrit \\\u003C 35%\n* TSH \\\u003C 0.4 o4 \\> 5.5\n* AST or ALT in excess of 2X the upper limit of normal\n* Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide\n* Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2","89 Years",{"count":518,"type":22},600,[520],"PHASE1","Overweight\u002Fobese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims:\n\n1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated first phase insulin secretion in the two FSIGTs (before and after administration of drug).\n2. Specific Aim #2. To identify genetic variants associated with the effect of a GLP1R agonist to accelerate the rate of glucose disappearance as assessed in the two FSIGTs (before and after administration of drug).\n\nGenotyping will be conducted using a high-density array with comprehensive coverage of DNA sequence variants. In addition, the analysis will leverage a global imputation panel generated from 1,025 Amish individuals.",[523,524],"Obesity","Diabetes Type 2",[526,527,528,529,530],"GLP-1 receptor agonist","Insulin secretion","Insulin sensitivity","Pharmacogenomics","Semaglutide",{"date":345,"type":38},{"date":533,"type":38},"2022-04-11",{"date":535,"type":22},"2028-04",{"name":44,"class":45},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":544,"maxAge":359,"enrollmentInfo":545,"targetDuration":4,"studyType":23,"phases":547,"briefSummary":548,"conditions":549,"keywords":551,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":562},"100547153","phase-1-facilitating-neuroplastic-changes-of-acute-stroke-survivors-100547153","NCT06404268","Facilitating Neuroplastic Changes of Acute Stroke Survivors","Facilitating Neuroplastic Changes of Acute Stroke Survivors With Severe Hemiplegia","Inclusion Criteria:\n\n* Acute first time unilateral hemispheric stroke (hemorrhagic or ischemic stroke, 24 hours after admission to 1 month post-stroke at the start of the proposed treatment)\n* Hemiplegia or hemiparesis\n* 0≤Manual Muscle Testing (MMT)\\\u003C=2\n* Age 30-85\n* Ankle impairments including stiff calf muscles and\u002For inadequate dorsiflexion\n\nExclusion Criteria:\n\n* Medically not stable\n* Associated acute medical illness that interferes with ability to training and exercise\n* No impairment or very mild ankle impairment of ankle\n* Severe cardiovascular problems that interfere with ability to perform moderate movement exercises\n* Cognitive impairment or aphasia with inability to follow instructions\n* Severe pain in legs\n* Severe ankle contracture greater than 15° plantar flexion (when pushing ankle to dorsiflexion)\n* Pressure ulcer, recent surgical incision or active skin disease with open wounds present below knee","30 Years",{"count":546,"type":22},68,[520,79],"This project will develop a wearable rehabilitation robot suitable for in-bed acute stage rehabilitation. It involves robot-guided motor relearning, passive and active motor-sensory rehabilitation early in the acute stage post-stroke including patients who are paralyzed with no motor output. The early acute stroke rehabilitation device will be evaluated in this clinical trial.",[550],"Stroke",[550,552,553],"Paraplegia","Acute","2026-07-22",{"date":556,"type":38},"2026-07-23",{"date":558,"type":38},"2025-06-01",{"date":560,"type":22},"2028-08-31",{"name":44,"class":45},3,{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":570,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":583},"100505256","phase-2-testing-the-pain-clinical-practice-guideline-100505256","NCT05858996","Testing the Pain Clinical Practice Guideline","Testing the Pain Clinical Practice Guideline Using the Evidence Integration Triangle","Inclusion Criteria:\n\n* Living in a participating community\n* 60 years of age or older\n* Evidence of dementia based on a score of 0-12 on the Brief Interview of Mental Status (BIMS); a score of \\>2 on the AD8 Dementia Screening Interview; a score of 0.5 to 2.0 on the Clinical Dementia Rating Scale (CDR); and lastly to differentiate between dementia and mild cognitive impairment a score of 9 or greater on the Functional Activities Questionnaire (FAQ).\n* have evidence of pain at the time of recruitment based on the Minimum Data set assessment item: How much of the time over the past 5 days have you experienced pain or hurting with eligibility based on the following responses or evidence: occasionally, frequently or almost constantly, or staff report of pain at the same frequency; or if the resident is receiving nonpharmacological or pharmacological treatment for pain.\n\nExclusion Criteria:\n\n* admitted to the nursing home for short-stay rehabilitation or other subacute needs (e.g., intravenous antibiotics);\n* receiving Hospice care.","60 Years",{"count":572,"type":22},300,[79],"There are evidence based processes for assessment and management of pain using pharmacologic and nonpharmacological approaches. These were reviewed and included within the Pain Management Clinical Practice Guideline (Pain Management CPG) recently developed by AMDA: The Society for Post-Acute and Long-Term Care Medicine. There are, however, many challenges to translating the use of Clinical Practice Guidelines into clinical settings. To overcome these challenges we developed and previously tested a theoretically based approach and merged this approach with the Pain Management CPG, which is referred to as the PAIN-CLINICAL PRACTICE GUIDELINE-USING THE EVIDENCE INTEGRATION TRIANGLE (PAIN-CPG-EIT). The PAIN-CPG-EIT involves a research nurse facilitator working with an identified community champion(s) and stakeholder team for 12 months to provide the following four components: Component I: Establishing and meeting monthly with a Stakeholder Team; Component II: Education of the staff; Component III: Mentoring and motivating the staff to address pain; Component IV: Ongoing evaluation of resident pain outcomes. Twelve communities will be included with 25 residents living with dementia and pain recruited from each community. Six communities will be randomized to treatment (PAIN-CPG-EIT) and six randomized to education only (EO) which involves providing the same education to staff as is done in Component II of PAIN-CPG-EIT. The primary aim of this study is to test the effectiveness of use of the PAIN-CPG-EIT to improve the assessment, diagnosis and management of pain and decrease pain intensity among nursing home residents living with dementia between baseline, 4 and 12 months and evaluate treatment fidelity. A secondary aim of the study is to consider differences in measurement, treatment and response to treatment between male and female and Black versus White residents living with dementia. Findings from this study will help build on the currently limited information about pain presentation and management among older adults living with dementia in nursing homes and improve health equity of aging populations experiencing pain.",[576,577],"Pain","Dementia",{"date":556,"type":38},{"date":580,"type":38},"2023-12-01",{"date":259,"type":22},{"name":44,"class":45},11,{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":588,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":544,"maxAge":359,"enrollmentInfo":589,"targetDuration":4,"studyType":23,"phases":590,"briefSummary":591,"conditions":592,"keywords":594,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":46},"100551838","promoting-neuroplastic-changes-of-patients-with-tbi-100551838","NCT06465290","Promoting Neuroplastic Changes of Patients With TBI",{"count":451,"type":22},[25],"This project will develop a wearable rehabilitation robot suitable for in-bed acute stage rehabilitation. It involves robot-guided motor relearning, passive and active motor-sensory rehabilitation early in the acute stage post-TBI including patients who are paralyzed with no motor output. The early acute TBI rehabilitation device will be evaluated in this clinical trial.",[593],"Traumatic Brain Injury",[595,552,553],"Traumatic Brain Injury (TBI)","2026-07-15",{"date":598,"type":38},"2026-07-17",{"date":600,"type":38},"2026-07-16",{"date":602,"type":22},"2030-08-31",{"name":44,"class":45},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":145,"sex":17,"minAge":18,"maxAge":359,"enrollmentInfo":612,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":614,"conditions":615,"keywords":616,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":46},"100236734","robot-aided-rehabilitation---multi-joint-evaluations-100236734","NCT02359812","Robot Aided Rehabilitation - Multi-joint Evaluations","Robot-Aided Diagnosis, Passive-Active Arm Motor and Sensory Rehabilitation Post Stroke: Aim 1","Aim1","Inclusion Criteria:\n\n1. First focal unilateral lesion, ischemic or hemorrhagic\n2. Had a stroke less than a month prior to enrollment\n3. Rated between stages 1-4 on the Chedoke McMaster Stroke Assessment Impairment Inventory: Stage of Recovery of the Arm\n4. Rated between stages 1-4 on the Chedoke McMaster Stroke Assessment Impairment Inventory: Stage of Recovery of the Hand\n\nExclusion Criteria:\n\n1. Apraxia\n2. Other unrelated or musculoskeletal injuries\n3. Unable to sit in a chair for 3 consecutive hours\n4. Score of less than 22 on the Mini Mental Status Exam\n5. Poor fit into equipment used in study which compromises proper use. This will be determined by the judgment of study staff",{"count":613,"type":22},56,"Sensory and motor impairments following stroke can lead to substantial disability involving the arm and hand. The investigator hypothesized that excessive local and cross-coupled stiffness, diminished individuation and proprioceptive acuity will be present among multiple degree of freedom in the upper limb. The stiffness and spasticity will increase with time post-stroke. The objective of this study is to quantify the progression throughout the arm and hand during recovery from stroke. The investigator will measure the clinical assessment scores, and neuromechanical properties including range of motion, active and passive cross coupling, and spasticity by the IntelliArm robot.",[550],[550,617,618,619,620,621,622,623],"Upper extremity","Rehabilitation","Robot","Hemiplegia","Spasticity","Arm","Hand",{"date":598,"type":38},{"date":626,"type":38},"2018-05-07",{"date":628,"type":22},"2027-05-31",{"name":44,"class":45},""]